MIR371B: A Potential Drug Target and Biomarker (G100616185)
MIR371B: A Potential Drug Target and Biomarker
Molecular Intelligence (MOI)
Molecular Intelligence (MOI) is a computational platform designed to predict the structure and function of proteins. It has been widely applied in drug discovery, where the identification of potential drug targets is a critical step. In this article, we discuss MIR371B, a protein that has potential as a drug target and biomarker.
MIR371B: Structure and Function
MIR371B is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and kidneys. It is a member of the superfamily of cytoskeletal proteins, which are involved in the regulation of cell shape and movement. MIR371B is characterized by a unique domain structure, which consists of a helical region, a parallel beta-sheet, and a terminal tail.
The helical region of MIR371B is known as the N-terminal alpha-helicase domain. This domain contains a highly conserved alpha-helicase enzyme active site, which is responsible for the hydrolysis of disulfide bonds in the protein. The parallel beta-sheet region is involved in the transmembrane portion of the protein and is known for its role in the regulation of ion and water transport. The terminal tail region is involved in the protein's stability and interacts with various cellular structures.
MIR371B functions as a negative regulator of the NF-kappa-B signaling pathway. NF-kappa-B is a non-coding RNA-protein complex that plays a crucial role in cell signaling and inflammation. MIR371B is involved in the regulation of NF-kappa-B activity by inhibiting the activity of the nuclear factor of activated T cells (NFAT), which is a transcription factor that regulates NF-kappa-B activity.
MIR371B has been shown to play a role in the pathogenesis of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, MIR371B has been shown to be involved in the development of neurofibrillary tangles, a hallmark of Alzheimer's disease, by regulating the production of beta-amyloid peptides.
Drug Target Potential
MIR371B is a drug target with potential for the treatment of various diseases. The inhibition of MIR371B activity by small molecules has been shown to be effective in animal models of cancer, neurodegenerative diseases, and autoimmune diseases.
One of the potential mechanisms by which MIR371B may be targeted is by its role in the regulation of NF-kappa-B activity. NF-kappa-B signaling is involved in the regulation of inflammation, cell growth, and survival, and is a target for many drugs used in cancer and neurodegenerative disease treatment. MIR371B inhibition of NF-kappa-B activity may be an effective way to treat these diseases.
Another potential mechanism by which MIR371B may be targeted is by its role in the regulation of cell shape and movement. MIR371B is involved in the regulation of actinin cytoskeleton, which is responsible for the maintenance of cell shape and integrity. MIR371B inhibition may be an effective way to treat diseases that are characterized by abnormal cell shape or movement, such as cancer.
Biomarker Potential
MIR371B is also a potential biomarker for the diagnosis and monitoring of various diseases. The regulation of NF-kappa-B activity by MIR371B is a well-established biomarker for the diagnosis of neurofibrillary tangles, which are a hallmark of Alzheimer's disease. MIR371B inhibition has been shown to be effective in animal models of
Protein Name: MicroRNA 371b
The "MIR371B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR371B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR372 | MIR373 | MIR374A | MIR374B | MIR374C | MIR375 | MIR376A1 | MIR376A2 | MIR376B | MIR376C | MIR377 | MIR378A | MIR378B | MIR378C | MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G | MIR378H | MIR378I | MIR379 | MIR380 | MIR381 | MIR382 | MIR383 | MIR384 | MIR3907 | MIR3908 | MIR3909 | MIR3910-1 | MIR3910-2 | MIR3911 | MIR3912 | MIR3913-1 | MIR3913-2 | MIR3914-1 | MIR3914-2 | MIR3915 | MIR3916 | MIR3917 | MIR3918 | MIR3919 | MIR3920 | MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265
